Your browser doesn't support javascript.
loading
Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients.
Larosa, Maddalena; Le Guern, Véronique; Morel, Nathalie; Belhocine, Mériem; Ruffatti, Amelia; Silva, Nicolas Martin; Paule, Romain; Mouthon, Luc; Dreyfus, Michel; Piette, Jean-Charles; Souchaud-Debouverie, Odile; Deneux-Tharaux, Catherine; Guettrot-Imbert, Gaelle; Tsatsaris, Vassilis; Pannier-Metzger, Emmanuelle; Murarasu, Anne; Doria, Andrea; Costedoat-Chalumeau, Nathalie.
Afiliação
  • Larosa M; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Le Guern V; Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
  • Morel N; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Belhocine M; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Ruffatti A; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Silva NM; Sacré-Coeur Hospital, Internal Medicine Department, University of Montréal, Montréal, Canada.
  • Paule R; Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
  • Mouthon L; University Hospital Center of Caen, Department of Internal Medicine, Caen, France.
  • Dreyfus M; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Piette JC; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Souchaud-Debouverie O; Université de Paris, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
  • Deneux-Tharaux C; University Hospital Center of Caen, Gynecology and Obstetrics Department, Caen, France.
  • Guettrot-Imbert G; AP-HP, Pitié-Salpétrière University Hospital, Internal Medicine and Clinical Immunology Department, Centre de référence maladies auto-immunes et systémiques rares de l'Ile de France, Paris, France.
  • Tsatsaris V; Poitiers University Hospital, Department of Medicine, Internal Medicine Department, Paris, France.
  • Pannier-Metzger E; INSERM U 1153, Obstetrical, Perinatal and Paediatric Epidemiology (EPOPé research team), DHU Risks in Pregnancy, Université de Paris, Paris, France.
  • Murarasu A; AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris, France.
  • Doria A; AP-HP, Cochin Broca Hôtel-Dieu Hospital, Port-Royal maternity, DHU Risk in Pregnancy, INSERM Unité 1139, Paris, France.
  • Costedoat-Chalumeau N; AP-HP, Cochin Broca Hôtel-Dieu Hospital, Port-Royal maternity, DHU Risk in Pregnancy, INSERM Unité 1139, Paris, France.
Arthritis Res Ther ; 23(1): 134, 2021 05 04.
Article em En | MEDLINE | ID: mdl-33947469
ABSTRACT

BACKGROUND:

The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS.

METHODS:

We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks' gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit.

RESULTS:

The 40 women had a mean age of 30.5 ± 4.6 years at their first episode of preeclampsia; 21 were nulligravid (52.5%), 12 (30%) had already been diagnosed with APS, and 21 (52.5%) had a triple-positive antiphospholipid (aPL) antibody test. Preeclampsia occurred at a median gestational age of 25.5 weeks (IQR 23-29). It was associated with HELLP in 18 cases (45%), eclampsia in 6 (15%), placental abruption in 3 (7.5%), catastrophic APS in 3 (7.5%), and foetal and neonatal death in 11 and 15 cases. Overall, 14 (35%) children survived, born at a median gestational age of 31 weeks. Among other APS criteria, 16 women (40%) experienced at least one thrombosis, 17 (42.5%) an intrauterine foetal death, and 19 (47.5%) at least one episode of HELLP during follow-up (median 5 years, IQR = 2-8). None had three or more consecutive miscarriages. Notably, 12 women (30%) had systemic lupus erythematosus.

CONCLUSIONS:

Severe preeclampsia led to high mortality in the offspring. Almost half of these women experienced other APS features, but not three consecutive miscarriages.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Eclâmpsia / Síndrome Antifosfolipídica Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Female / Humans / Infant / Newborn / Pregnancy País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Eclâmpsia / Síndrome Antifosfolipídica Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Female / Humans / Infant / Newborn / Pregnancy País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article